RESEARCH MONOGRAPH · KDC-MN-314

Latrepirdine (Dimebon)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

54/100

The cautionary tale of phase 2 to phase 3 attrition, with a residual mitochondrial story that's actually interesting

Latrepirdine is the textbook example of how a phase 2 home run can evaporate in phase 3. Doody and colleagues published the 2008 Lancet paper showing significant cognitive benefit in Alzheimer's patients, the field got excited, Medivation partnered with Pfizer, and then CONNECTION and CONCERT both missed. Hard. The story basically ended there for clinical purposes.

But the molecule itself is more interesting than the regulatory outcome suggests. It started life as a Russian antihistamine in the 80s, polypharmacology galore: H1 antagonism, weak NMDA channel blockade, low-affinity activity at a handful of monoaminergic targets, and the part that actually keeps us interested, mitochondrial membrane stabilization. Bharadwaj and Bredesen's work, plus the Reddy lab papers, showed effects on mitochondrial permeability transition pore opening at low nM concentrations. Thats not nothing.

The phase 3 failure most likely reflects two things: the original Russian patient population was probably not comparable to the US/EU trial population (selection, diagnostic criteria, baseline severity), and the mechanism, whatever it actually is, wasnt strong enough to overcome the noise in a larger heterogeneous AD population.

What we like as a research tool: it's a well-characterized mito-protective small molecule with documented effects on Ca2+ handling and ROS in neuronal cultures. If you're doing mitochondrial bioenergetics work, particularly in models of neurodegeneration, it's a useful comparator alongside MitoQ, SS-31, or olesoxime. The huntingtin-aggregation work from Bezprozvanny's group is also worth a read if you're in that space.

Sourcing is straightforward, dihydrochloride salt is the standard form, stable, water-soluble enough for most assays. HPLC verification is easy. Vendors that have it usually have it cheap because demand collapsed after the trial failures.

What we dont like is the temptation to over-interpret the mito signal. The therapeutic story didnt translate and a lot of the cell-culture work was done at concentrations well above what you'd reach in vivo. Useful for mechanism studies, not a serious therapeutic candidate anymore.

Mostly a museum piece with a couple of decent uses left.

Evidence: 45
Mechanism: 55
Reliability: 35
Safety: 65
Sourcing: 80
Value: 70
Signal: 40
Staying power: 40

Plain-language summary Intrigue 42 / 100

Latrepirdine (Dimebon) is a Soviet-era antihistamine that was sold for decades in Russia for ordinary allergies before being repurposed for Alzheimer disease. It blocks several receptors at once (histamine, serotonin, dopamine, adrenergic) and may also protect mitochondria, the cellular power plants. A 2008 phase 2 trial in Alzheimer patients showed striking benefit and triggered enormous interest, but two large phase 3 trials in 2010 to 2012 (CONNECTION and CONCERT) failed completely. The collapse is one of the most cited cautionary tales in CNS drug development. The compound is no longer in clinical development and survives mainly as a research tool for studying multi-target receptor pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Multi-target antihistamine / mitochondrial protectant

A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

Abstract

Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

Mechanism of action

Multi-target receptor antagonist (H1, alpha-1/2, 5-HT2A/5A/6, D1/2). Possible mitochondrial protective activity. Phase 3 efficacy not replicated.

Reported research dose ranges

Trial doses 5 to 20 mg in the published literature.

References

Doody RS, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008.
Doody RS, et al. A phase 3 trial of latrepirdine in patients with mild to moderate Alzheimer's disease. Arch Neurol 2014.
Bachurin SO, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-314

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Latrepirdine (Dimebon)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs